TR200300766T2 - A1 adenosin reseptörü antagonistleri olarak yoğunlaştırılmış purin türevleri. - Google Patents

A1 adenosin reseptörü antagonistleri olarak yoğunlaştırılmış purin türevleri.

Info

Publication number
TR200300766T2
TR200300766T2 TR2003/00766T TR200300766T TR200300766T2 TR 200300766 T2 TR200300766 T2 TR 200300766T2 TR 2003/00766 T TR2003/00766 T TR 2003/00766T TR 200300766 T TR200300766 T TR 200300766T TR 200300766 T2 TR200300766 T2 TR 200300766T2
Authority
TR
Turkey
Prior art keywords
receptor antagonists
adenosine receptor
purine derivatives
condensed purine
compounds
Prior art date
Application number
TR2003/00766T
Other languages
English (en)
Inventor
Lin Ko-Chung
Vu Chi
Original Assignee
Biogen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Inc. filed Critical Biogen, Inc.
Publication of TR200300766T2 publication Critical patent/TR200300766T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A1 alt-tipi adenosin reseptörlerinin antagonistler olarak Ive II formüllerinin bilesikleri anlatilmistir. Bu bilesikler, aralarinda, sistemik hipertansiyon, böbrek bozuklugu, diyabet, astim ve ödemli bir durum, konjestif kalp bozuklugu ve renal islev bozuklugu bulunan çesitli hastaliklar ve bozukluklarin iyilestirilmesi için yararli olmaktadirlar.
TR2003/00766T 2000-12-01 2001-11-30 A1 adenosin reseptörü antagonistleri olarak yoğunlaştırılmış purin türevleri. TR200300766T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25065800P 2000-12-01 2000-12-01

Publications (1)

Publication Number Publication Date
TR200300766T2 true TR200300766T2 (tr) 2004-09-21

Family

ID=22948640

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2003/00766T TR200300766T2 (tr) 2000-12-01 2001-11-30 A1 adenosin reseptörü antagonistleri olarak yoğunlaştırılmış purin türevleri.

Country Status (33)

Country Link
US (2) US6605601B2 (tr)
EP (1) EP1347981B1 (tr)
JP (2) JP2004514723A (tr)
KR (1) KR20040011439A (tr)
CN (1) CN100497340C (tr)
AR (1) AR035400A1 (tr)
AT (1) ATE394402T1 (tr)
AU (2) AU1997702A (tr)
BG (1) BG107849A (tr)
BR (1) BR0115833A (tr)
CA (1) CA2430508C (tr)
CZ (1) CZ20031513A3 (tr)
DE (1) DE60133931D1 (tr)
EA (1) EA009814B1 (tr)
EE (1) EE200300260A (tr)
ES (1) ES2305139T3 (tr)
GE (1) GEP20094697B (tr)
HK (1) HK1059927A1 (tr)
HU (1) HUP0400530A3 (tr)
IL (1) IL156046A0 (tr)
IS (1) IS6821A (tr)
MX (1) MXPA03004857A (tr)
MY (1) MY127120A (tr)
NO (1) NO20032483L (tr)
NZ (1) NZ526511A (tr)
PL (1) PL362642A1 (tr)
SK (1) SK6552003A3 (tr)
TR (1) TR200300766T2 (tr)
TW (1) TWI293301B (tr)
UA (1) UA75625C2 (tr)
WO (1) WO2002044182A1 (tr)
YU (1) YU42903A (tr)
ZA (2) ZA200304067B (tr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7005430B2 (en) * 1999-12-24 2006-02-28 Kyowa Hakko Kogyo Co., Ltd. Fused purine derivatives
CZ20031513A3 (cs) * 2000-12-01 2003-09-17 Biogen, Inc. Kondenzované purinové deriváty jako antagonisty A1 adenosinového receptoru
CA2516250A1 (en) * 2003-02-19 2004-09-02 Endacea, Inc. A1 adenosine receptor antagonists
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
MXPA05011371A (es) 2003-04-25 2005-12-01 Novacardia Inc Metodo para mejorar la diuresis en individuos con la funcion renal deteriorada.
CN1777608A (zh) * 2003-04-25 2006-05-24 协和发酵工业株式会社 稠合嘧啶衍生物
WO2005009343A2 (en) * 2003-06-06 2005-02-03 Endacea, Inc. A1 adenosine receptor antogonists
US20080161327A1 (en) * 2005-03-11 2008-07-03 Aderis Pharmaceuticals, Inc. Substituted 9-Alkyladenines and the Use Thereof
US7795427B2 (en) * 2006-02-14 2010-09-14 New York University Methods for inhibiting osteoclast differentiation, formation, or function and for increasing bone mass
JP2009532479A (ja) * 2006-04-06 2009-09-10 ノヴァカーディア，インク． アデノシンａ１受容体アンタゴニストと抗痙攣薬の同時投与
DK2018380T3 (da) 2006-05-19 2012-01-23 Abbott Lab CNS-aktiverede kondenserede bi-heterocyklisk-substituerede azabicykliske alkanderivater
EP2035009A1 (en) * 2006-06-16 2009-03-18 Novacardia, Inc. Prolonged improvement of renal function comprising infrequent administration of an aa1ra
AR061625A1 (es) 2006-06-23 2008-09-10 Incyte Corp Derivados de purinona como agonistas de hm74a
DE602007010312D1 (de) 2006-06-23 2010-12-16 Incyte Corp Purinonderivate als hm74a-agonisten
WO2008121893A1 (en) * 2007-03-29 2008-10-09 Novacardia, Inc. Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist
US20080242684A1 (en) * 2007-03-29 2008-10-02 Howard Dittrich Methods of administration of adenosine a1 receptor antagonists
WO2011063268A2 (en) * 2009-11-19 2011-05-26 Biogen Idec Ma Inc Novel synthetic methods
WO2011123518A1 (en) 2010-03-31 2011-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenosine receptor agonists for the treatment and prevention of vascular or joint capsule calcification disorders
CN111770926B (zh) * 2018-01-04 2023-07-21 因佩蒂斯生物科学有限公司 三环化合物、组合物及其医药应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06102662B2 (ja) * 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
ES2152207T3 (es) * 1989-10-20 2001-02-01 Kyowa Hakko Kogyo Kk Derivados condensados de la purina.
ATE349424T1 (de) 1991-09-23 2007-01-15 Univ Florida State Beta-lactame verwendbar zur herstellung von substituierten isoserinestern mit metallalkoxiden
EP0884318A4 (en) * 1996-10-07 2002-10-23 Kyowa Hakko Kogyo Kk CONDENSED PURINE DERIVATIVES
EP1014995A4 (en) * 1997-06-18 2005-02-16 Aderis Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR PREVENTING RESTENOSES CONSECUTIVE TO REVASCULARIZATION INTERVENTIONS
US6489331B1 (en) * 1998-07-02 2002-12-03 Kyowa Hakko Kogyo Co., Ltd. Remedies for diabetes
US7005430B2 (en) * 1999-12-24 2006-02-28 Kyowa Hakko Kogyo Co., Ltd. Fused purine derivatives
CZ20031513A3 (cs) * 2000-12-01 2003-09-17 Biogen, Inc. Kondenzované purinové deriváty jako antagonisty A1 adenosinového receptoru

Also Published As

Publication number Publication date
MXPA03004857A (es) 2003-08-19
ES2305139T3 (es) 2008-11-01
EE200300260A (et) 2003-08-15
CA2430508C (en) 2010-05-18
NO20032483D0 (no) 2003-06-02
IS6821A (is) 2003-05-20
YU42903A (sh) 2006-05-25
ATE394402T1 (de) 2008-05-15
BR0115833A (pt) 2003-10-28
NO20032483L (no) 2003-07-30
NZ526511A (en) 2005-04-29
MY127120A (en) 2006-11-30
SK6552003A3 (en) 2003-12-02
GEP20094697B (en) 2009-06-10
JP2004514723A (ja) 2004-05-20
BG107849A (bg) 2004-01-30
ZA200304067B (en) 2005-05-30
EA009814B1 (ru) 2008-04-28
CZ20031513A3 (cs) 2003-09-17
US20030220358A1 (en) 2003-11-27
US20020111333A1 (en) 2002-08-15
HUP0400530A2 (hu) 2004-06-28
US7022686B2 (en) 2006-04-04
UA75625C2 (en) 2006-05-15
HUP0400530A3 (en) 2007-05-29
JP2010053148A (ja) 2010-03-11
AR035400A1 (es) 2004-05-26
DE60133931D1 (de) 2008-06-19
US6605601B2 (en) 2003-08-12
AU2002219977B2 (en) 2008-01-24
AU1997702A (en) 2002-06-11
KR20040011439A (ko) 2004-02-05
PL362642A1 (en) 2004-11-02
CA2430508A1 (en) 2002-06-06
WO2002044182A1 (en) 2002-06-06
TWI293301B (en) 2008-02-11
HK1059927A1 (en) 2004-07-23
EA200300629A1 (ru) 2003-12-25
CN1481387A (zh) 2004-03-10
EP1347981B1 (en) 2008-05-07
ZA200408755B (en) 2005-07-27
IL156046A0 (en) 2003-12-23
CN100497340C (zh) 2009-06-10
EP1347981A1 (en) 2003-10-01

Similar Documents

Publication Publication Date Title
TR200300766T2 (tr) A1 adenosin reseptörü antagonistleri olarak yoğunlaştırılmış purin türevleri.
TR200002097A2 (tr) Triazol ve imidazol türevleri
UY27098A1 (es) Derivados de indol
EA200200560A1 (ru) Полициклоалкилпурины в качестве антагонистов аденозиновых рецепторов
CY1106424T1 (el) Παραγωγα ν-φαινυλ-πυρρολ γουανιδινης ως συνδετες υποδοχεις μελανοκορτινης
EA200601160A1 (ru) 2,6-бисгетероарил-4-аминопиримидины в качестве антагонистов аденозиновых рецепторов
TR199802269T2 (tr) Endotelin reseptör antagonistleri olarak faydali indol türevleri.
AR017296A1 (es) Uso de un antagonista del receptor de 5-hidroxitriptamina y compuestos antagonistas
ATE479686T1 (de) Pyridopyrrolizin- und pyridoindolizinderivate
DE60215000D1 (de) DIHYDROPYRROLOi1,2-AöINDOL- UND TETRAHYDROPYRIDOi1,2-AöINDOLDERIVATE ALS PROSTAGLANDIN REZEPTOR ANTAGONISTEN
PT1513826E (pt) Novos derivados de indolilpiperidina como agentes anti-histaminicos e antialergicos potentes
BR0315959A (pt) Composto, composição farmacêutica uso do composto, método para o tratamento, método para reduzir a morbidez e a mortalidade associadas com o excesso de peso e processo para a preparação do composto
CY1108457T1 (el) Παραγωγα ξανθινης ως ανταγωνισται υποδοχεως α2β αδενοσινης
NO20052866L (no) Imidazokinolinderivater som adenosin A3 reseptorligander
ATE418555T1 (de) A2a-adenosinrezeptorantagonisten
BR0007864A (pt) Composto, e, uso de um composto
DK1149078T3 (da) Selektive 5-HT6-receptorligander
DE69626705T2 (de) A1 adenosin rezeptor agonisten und antagonisten
ATE119524T1 (de) Substituierte n-(imidazolyl)alkyl-alanin- derivate.
JP2004511522A5 (tr)
TR200001141T2 (tr) Motilin reseptörü antagonistleri olarak yararlı siklopenten türevleri.
MEP19108A (en) Aminoquinoline derivatives and their use as adenosine a3 ligands
CR9058A (es) Derivados de indol como inhibidores de la adenilato ciclasa soluble
NO20002655L (no) 5-(2-imidazolinylamino) -benzimidazol derivater, fremstilling og anvendelse derav som <alfa>-adrenoceptoragonister med forbedret metabolisk stabilitet
ATE227276T1 (de) Neue pyrimidinderivate